Cargando…

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study

BACKGROUND: We conducted a prospective cohort study at Kaiser Permanente Southern California to study the vaccine effectiveness (VE) of mRNA-1273 over time and during the emergence of the Delta variant. METHODS: The cohort for this planned interim analysis consisted of individuals aged ≥18 years rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Florea, Ana, Sy, Lina S., Luo, Yi, Qian, Lei, Bruxvoort, Katia J., Ackerson, Bradley K., Lee, Gina S., Ku, Jennifer H., Tubert, Julia E., Tian, Yun, Talarico, Carla A., Tseng, Hung Fu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049574/ https://www.ncbi.nlm.nih.gov/pubmed/35482785 http://dx.doi.org/10.1371/journal.pone.0267824

Ejemplares similares

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
por: Bruxvoort, Katia J., et al.
Publicado: (2021)

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

784. Real-world effectiveness of the mRNA-12733-dose primary series against COVID-19 in an immunocompromised population Interim results from a prospective observational cohort study
por: Ku, Jennifer H, et al.
Publicado: (2022)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

19. Completion of Two-Dose Recombinant Zoster Vaccine Series in Adults 50 Years and Older
por: Tseng, Hung-Fu, et al.
Publicado: (2020)

Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System — California, March–July 2021
por: Malden, Deborah E., et al.
Publicado: (2021)

Differences in Estimates of Post-Herpetic Neuralgia Between Medical Chart Review and Self-Report
por: Tanenbaum, Hilary C, et al.
Publicado: (2020)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence
por: Tseng, Hung Fu, et al.
Publicado: (2020)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19
por: Puranik, Arjun, et al.
Publicado: (2022)

2300. Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated Adults ≥50 Years of Age
por: Ackerson, Bradley, et al.
Publicado: (2019)

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Challenges in Phase 4 post-licensure safety studies using real world data in the United States: Hepatitis B vaccine example
por: Bruxvoort, Katia, et al.
Publicado: (2021)

917. Development and Validation of an Automated Natural Language Processing Method for Identifying Postherpetic Neuralgia from Electronic Health Records
por: Zheng, Chengyi, et al.
Publicado: (2023)

Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
por: Slezak, Jeff, et al.
Publicado: (2021)

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
por: Mateus, Jose, et al.
Publicado: (2021)

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
por: Tartof, Sara Y, et al.
Publicado: (2022)

115. Post-licensure Safety Study of New-onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis in Adult Recipients of HepB-CPG Vaccine Versus HepB-alum Vaccine
por: Ackerson, Bradley, et al.
Publicado: (2022)

Text-Based Identification of Herpes Zoster Ophthalmicus With Ocular Involvement in the Electronic Health Record: A Population-Based Study
por: Zheng, Chengyi, et al.
Publicado: (2021)

Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison
por: Chin, Elizabeth T., et al.
Publicado: (2021)

Association of Number of Doses With Hepatitis B Vaccine Series Completion in US Adults
por: Bruxvoort, Katia, et al.
Publicado: (2020)

mRNA-1273: Myocarditis: case report
Publicado: (2021)

mrna-1273: Erythema nodosum: case report
Publicado: (2021)

mrna-1273: Immediate hypersensitivity: case report
Publicado: (2021)

mrna-1273: Acute myocarditis: case report
Publicado: (2021)

mRNA-1273: Myopericarditis: case report
Publicado: (2021)

mRNA 1273: Anaphylaxis: case report
Publicado: (2021)

mrna-1273: Haematuria: 2 case reports
Publicado: (2021)

A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report
por: Masuda, Taisei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vhkrvrnrq3i1pdm7sk3mukbmt5